Rockwell Medical

About Rockwell Medical

Rockwell Medical, Inc. is a publicly traded healthcare company founded in 1996 by Robert L. Chioini, who identified an opportunity to more efficiently supply dialysis products. Headquartered in Wixom, Michigan, the firm develops, manufactures, and distributes a portfolio of hemodialysis products to dialysis providers globally. The company's business model is centered on generating revenue through the sale of its core products, primarily hemodialysis concentrates, which are essential for removing toxins during dialysis treatment. Rockwell is the second-largest supplier of these concentrates in the United States.

The company's primary revenue stream comes from product sales to dialysis clinics and distributors, which provides a recurring income base due to the essential nature of the treatments. Its product line includes liquid and dry acid and bicarbonate concentrates like CitraPure, Dri-Sate, and RenalPure. The company also generates revenue from international licensing agreements and partnerships. A significant milestone was the FDA approval of Triferic in January 2015, a therapy designed to replace iron and maintain hemoglobin in adult hemodialysis patients. However, due to limited market adoption and unfavorable reimbursement in the U.S., the company discontinued its New Drug Applications for Triferic and its intravenous version, Triferic AVNU, domestically in late 2022. Rockwell has since pivoted to commercializing these products through international partnerships in regions like South Korea and Turkey.

Financially, Rockwell Medical has focused on achieving profitability, reaching this goal on an adjusted EBITDA basis for the first time in its history for the full year 2024. The company reported record net sales of $101.5 million in 2024, a 21% increase from 2023. However, the company faces challenges, including a heavy reliance on a few major customers and the transition of its largest customer to another supplier in mid-2025, which has impacted revenues in 2025. In response, Rockwell is focused on diversifying its customer base and has secured multi-year agreements with several healthcare providers, bringing over 80% of its customers under long-term contracts.